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Vav1/2/3-null Mice Define an Essential Role for Vav Family
Proteins in Lymphocyte Development and Activation
but a Differential Requirement in MAPK Signaling
in T and B Cells
Keiko Fujikawa,1,3,4 Ana V. Miletic,3 Frederick W. Alt,1,2 Roberta Faccio,3
Tracie Brown,3 Jeremy Hoog,3 Jessica Fredericks,3 Shinzo Nishi,4 Shirly Mildiner,3
Sheri L. Moores,5 Joan Brugge,5 Fred S. Rosen,1 and Wojciech Swat1,3

Abstract
The Vav family of Rho guanine nucleotide exchange factors is thought to orchestrate signaling
events downstream of lymphocyte antigen receptors. Elucidation of Vav function has been
obscured thus far by the expression of three highly related family members. We generated mice
lacking all Vav family proteins and show that Vav-null mice produce no functional T or B cells
and completely fail to mount both T-dependent and T-independent humoral responses.
Whereas T cell development is blocked at an early stage in the thymus, immature B lineage
cells accumulate in the periphery but arrest at a late “transitional” stage. Mechanistically, we
show that the Vav family is crucial for both TCR and B cell receptor (BCR)–induced Ca2
signaling and, surprisingly, is only required for mitogen-activated protein kinase (MAPK) activation in developing and mature T cells but not in B cells. Thus, the abundance of immature B
cells generated in Vav-null mice may be due to intact Ras/MAPK signaling in this lineage.
Although the expression of Vav1 alone is sufficient for normal lymphocyte development, our
data also reveal lineage-specific roles for Vav2 and Vav3, with the first demonstration that Vav3
plays a critical compensatory function in T cells. Together, we define an essential role for the
entire Vav protein family in lymphocyte development and activation and establish the limits of
functional redundancy both within this family and between Vav and other Rho–guanine nucleotide exchange factors.
Key words: thymocyte • antigen receptor • signal transduction • Ca • mitogen-activated
protein kinase

Introduction
T and B lymphocytes differentiate along an ordered program
controlled by crucial signals emanating from surface receptors
(1). In the T cell lineage, the expression of the pre-TCR
induces both differentiation and proliferative expansion of

the pool of thymic progenitors, presumably effected by
Ras/mitogen activated protein kinase (MAPK) signaling
(2–6). In a parallel pathway, the pre–B cell receptor (preBCR) induces differentiation and expansion of the pool of
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pre–B cells (7–9). Since antigen receptors of both immature and mature lymphocytes lack any intrinsic signaling
capability, the pre-TCR or pre-BCR, and the TCR or
BCR, transmit their signals via associated transmembrane
chains (CD3 and TCR in T cells or Ig and Ig in B
cells) (10–13) that become tyrosine phosphorylated and
recruit adaptor proteins (14, 15) and Vav guanine nucleotide exchange factors (GEFs) (16, 17). Subsequent activation of phosphoinositide 3-OH kinase and phospholipase
C (PLC)1/2 generates second messengers diacylglycerol
(DAG) and inositol triphosphate that induce Ras/MAPK
or Ca2 signaling, respectively (10–13).
The Vav family of three highly conserved Rho-GEFs
was initially implicated in signaling downstream of both the
TCR and BCR by virtue of inducible tyrosine phosphorylation and the presence of structural domains characteristic
of proteins involved in signal transduction (16, 17). Receptor-induced tyrosine phosphorylation and the presence of
SH2 and SH3 domains distinguish Vav proteins from the
plethora of over 50 known mammalian Rho-GEFs (18).
Thus, Vav proteins can interact directly with several tyrosine kinases (through SH2 domain interactions with tyrosine phosphorylation sites) and indirectly with activated tyrosine kinases by binding to adaptor proteins that contain
SH2 and/or SH3 binding motifs. Like Vav1 (19, 20), Vav2
and Vav3 are inducibly phosphorylated after stimulation of
antigen receptors in immortalized T and B cell lines (21,
22); however, overexpression studies indicate functional
differences in the activities of the three family members in
coupling to distinct downstream pathways (16, 17). As exchange factors for Rho GTPases, Vav proteins have the potential to regulate antigen receptor–induced actin cytoskeletal rearrangements and other Rho-GTPase–regulated
cellular pathways (16, 17). Indeed, loss of Vav1 prevents efficient capping of the TCR through effects on actin polymerization (23, 24). Although the exact mode of Vav regulation in vivo is currently unknown, it is thought that the
exchange activity of the DH domain, responsible for regulation of Rho-GTPases, may be controlled by tyrosine
phosphorylation of an NH2-terminal autoinhibitory extension (25); however, Vav may have both DH-dependent
and DH-independent functions in T cells (26).
The importance of Vav1 in lymphocytes was first demonstrated in mice lacking Vav1 (Vav1ko) which showed activation defects in T and B lymphocytes (27–30) and in NK
(31) and  T cells (32). However, virtually all of those defects were partial, and Vav1ko mice still developed significant numbers of T cells, whereas development of B cells
was nearly intact (27–30). Moreover, Vav1ko lymphocytes
retained significant functional ability, presumably due to
redundancy between Vav family members. Indeed, analyses
of mice deficient in both Vav1 and Vav2 revealed a compensatory function for Vav2 in B lineage cell development
and function (33, 34). Although its role in T cell activation
has not yet been defined, Vav2 did not appear to have any
major function in T cell development (33, 34). Little is
known about the function of Vav3 in primary lymphocytes, but analyses of Jurkat T cells (21, 22) and a Vav31596

deficient chicken DT40 B cell line (35) suggest that it is involved in both TCR and BCR signaling. Since mice lacking all three Vav proteins have not yet been reported, efforts to define the role of the entire Vav family in
lymphocytes have been complicated by the functional redundancy among individual family members.
In this report, we generate mice congenitally lacking all
three Vav isoforms and present analyses of lymphocyte development and function. We provide genetic and biochemical evidence that the Vav family is critical and nonredundant in T and B lymphocyte development and function
and is essential in the formation of the adaptive immune
system. Although the involvement of Vav1 and Vav2 in
Ca2 signaling is well documented (23, 24, 29, 33, 34), our
analyses establish that the entire Vav family is indispensable
for both TCR- and BCR-induced Ca2 fluxes. Notably,
we observed a dissociation in Vav function at the level of
MAPK signaling in which Vav was required in T cells but
not in B cells.

Materials and Methods
RNase Protection Assays. To generate antisense riboprobes, a
198-bp cDNA fragment of murine Vav1 (nucleotides 664–862), a
200-bp cDNA fragment of murine Vav2 (nucleotides 652–852),
and a 197-bp cDNA fragment of murine Vav3 (nucleotides 676–
873) were generated by RT-PCR using either thymus (Vav1) or
spleen RNA (Vav2, Vav3). Each fragment was sequenced and
subcloned into pBluescript II SK in antisense orientation with respect to the T7 promoter. Riboprobes were synthesized with T7
RNA polymerase, labeled with -32P UTP, and PAGE purified.
RNase protection assay was performed essentially as described
(43) with minor modifications. Briefly, 2.5 g of total RNA
from each sample was hybridized with antisense RNA probes
(105 cpm) in 30 l of 80% formamide, 40 mM PIPES, pH 6.5,
1 mM EDTA, and 0.4 M NaCl at 45 C overnight. The hybrids
were digested in 400 l of 10 mM Tris-HCl, pH 7.5, 5 mM
EDTA, 0.3 M NaCl, and 5 g/ml RNase A at 30 C for 30 min.
After proteinase K treatment (125 g/ml, 37 C, 30 min) and
phenol/chloroform extraction, the protected RNA probes were
analyzed by 6% PAGE containing 8 M urea. Signal was detected
using x-ray film or PhosphorImager scanning with the same exposure time for all samples, and data was analyzed with ImageQuant software (Molecular Dynamics). RNA was isolated using Trizol reagent (Invitrogen).
Generation of Vav3-deficient Mice. Murine vav3 genomic
clones were obtained by screening a 129 strain phage genomic library (Stratagene) with a 438-bp fragment (probe K) corresponding to nucleotides 1,140–1,578 of murine vav3 cDNA, which
was generated as described previously (22). This yielded several
overlapping vav3 genomic fragments. One of the clones extending toward the 5 end was used to generate a new probe, which
included the 5 end of DH domain–encoding sequences (probe
H). Using both probes, four overlapping clones were characterized that included exons 3–17. A targeting construct was made to
replace exon 10, encoding part of the DH domain, with the neomycin-resistance gene in the reverse transcriptional orientation. A
thymidine kinase (tk) gene was used for negative selection of cells
with randomly integrated constructs. The targeting construct was
linearized and transfected into TC-1 ES cells by electroporation.
Positive and negative selection of transfectants was performed in
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media containing G418 (0.4 mg/ml) and gancyclovir (1 M).
Genomic DNA from individual double resistant (G418 and gancyclovir) clones was digested with EcoRI and probed with a 5
flanking probe on the Southern blot. Several targeted clones were
identified by the presence of a 6.8-kb EcoRI band upon hybridization with the 5 probe, and KpnI digestions were performed to
ensure proper homologous recombination at the 3 end of the
targeted region, as identified by hybridization of a 22.0-kb KpnI
band with the Neo probe. To rule out any undesired integration
events, EcoRI-digested DNA was also hybridized with the Neo
probe. Two independently derived heterozygous Vav3 mutant
ES cells were subcloned and injected into C57BL/6 blastocysts to
generate somatic chimera mice, which were bred with C57BL/6
females to transmit the targeted allele to the germline. F1 heterozygotes were then intercrossed to generate homozygous mutant mice.
Generation of Vav3 Antibodies. To generate polyclonal Vav3
antibodies, we immunized rabbits with a fusion protein comprising glutathione S-transferase and a Vav3 fragment, including the
DH and PH domains (aa 357–525) expressed in Escherichia coli,
using standard methods. The specificity of these antibodies for
Vav3 and the lack of cross-reactivity with other family members
was confirmed by Western blotting of cell lysates of 293T cells
transiently transfected with either an empty vector or expression
constructs encoding GFP fusions of Vav1, Vav2, or Vav3. mAbs
against murine Vav3 were raised by producing a recombinant
glutathione S-transferase–Vav3 fusion protein (encompassing 230
aa including the PH and the NH2-terminal SH3 domains) expressed in E. coli and purified over a glutathione-Sepharose column (Amersham Biosciences), which was used for immunization
of Vav3-deficient mice. Splenocytes of the immunized mouse
were fused with P3U1 mouse myeloma cells, and hybridoma
clones were selected and screened for binding to a maltose binding protein–Vav-3 fusion protein by ELISA. One positive hybridoma clone, 6D42, IgG1 isotype, was established and used for
production of mAbs, which showed no cross-reactivity with
Vav1 or Vav2.
Mice, Cell Suspensions, Antibodies, and Flow Cytometry. Germline Vav1 / and Vav2 / mice were described previously (29,
34) and were gifts from Dr. Tybulewicz (National Institute for
Medical Research, London, UK) and Dr. Turner (The Babraham
Institute, Cambridge, MA). These mice were bred with Vav3deficient mice in the mixed B6/129 background and maintained
in the SPF facility of Washington University School of Medicine.
All mice analyzed in this report were littermates derived from
mating heterozygous animals. Cell suspensions were prepared,
counted, and stained with antibodies following standard procedures. The following antibody conjugates were used (BD Biosciences): phycoerythrin (PE)-H129.19 (anti-CD4), fluorescein
(FITC)-, PE-, cytochrome C (CyC)–, or biotin–53–6.7 (antiCD8), PE-3C7, or FITC-7D4 (anti-IL2R), FITC-145–2C11
(anti-CD3 ), CyC-RA3–6B2 (anti-B220), PE-B3B4 (antiCD23), and FITC-7G6 (anti-CD21/35). Biotinylated antibodies
were detected with streptavidin (SAV)-PE or SAV-CyC (BD
Biosciences). Subsets of double negative (DN) thymocytes were
analyzed based on expression of CD44 and CD25 after gating out
all cells staining with a cocktail of biotinylated antibodies to CD4,
CD8, B220, Mac-1, and Gr-1, followed by Streptavidin CyChrome (BD Biosciences). For intracellular staining of TCR,
cells were first stained with PE-CD4 and Cy-Chrome-CD8.
Subsequently, cells were fixed, permeabilized in 1% saponin, and
stained with FITC-labeled anti-C–specific antibodies (H57
clone) and analyzed on FACSCalibur flow cytometer (Becton
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Dickinson) with CellQuest or FlowJo software. Data are displayed as histograms or dot plots with logarithmic scale. Each plot
represents analysis of 2  105 events collected as listmode files.
T and B Cell Stimulation and Proliferation Assays. T cells were
purified from LN cell suspensions by magnetic sorting and removal of B cells with anti-Ig–coated Dynabeads (Dynal) to avoid
receptor cross-linking during the purification process using standard procedures. The purity of resulting T cells exceeded 90% as
confirmed by FACS® analysis. B cells were purified from spleen
cell suspensions by magnetic removal of cells stained with biotinylated antibodies anti-Thy1.2, CD4, CD8, CD3, Mac-1, and
Gr-1 using streptavidin-coated Dynabeads (Dynal). Purity of B
cells was confirmed in each preparation by FACS® analysis and
exceeded 85%. Lymphocytes were cultured in DME medium
supplemented with 10% FCS, pen/strep, l-glutamine, Na-pyruvate, nonessential amino acids, and 2-mercaptoethanol. T cells
were stimulated at 5  106 cells/ml with either soluble or platebound anti-CD3 antibodies (2C11; a gift from Dr. Kanagawa,
Washington University, St. Louis, MO) (0.01–10 g/ml as indicated) and/or anti-CD28 (2 g/ml) (NA/LE formula; BD Biosciences) as indicated, and B cells were stimulated with soluble
anti-IgM Fab2 fragments (10 g/ml) (Jackson ImmunoResearch
Laboratories) for the indicated times at 37 C. For proliferation assays, purified T and B lymphocytes were cultured at a concentration of 5  104 cells/100 l in 96-well flat-bottom tissue culture
plates as indicated. Cells were pulsed with 1 Ci 3H-thymidine at
48 h for an additional 12 to 16 h and then collected and scintillation counted. The data are displayed as raw cpm values. All assays
were conducted in triplicates.
Immunizations and Antigen-specific Ig ELISA. To determine
the T-independent type 2 (TI-2) immune response, 6–8-wk-old
mice were immunized intraperitoneally with 100 g trinitrophenyl (TNP)-Ficoll (Biosearch Technologies) in alum (Pierce
Chemical Co.). T-dependent (TD) immune response was determined by injection of 100 g TNP-KLH (Biosearch Technologies) in alum. Mice were bled before immunization (day 0) and at
days 7 and 14. After boost with 100 g antigen at day 14, mice
were bled at days 21 and 28. Concentrations of TNP-specific serum antibody isotypes were determined by ELISA. ELISA plates
(Nunc Maxisorp) were coated at 100 l/well with 5 mg/ml
TNP-BSA (Biosearch Technologies) or with PBS only, as a control, and incubated overnight at 4 C. After overnight incubation,
plates were washed three times with wash buffer (Tris-Cl, pH
7.6, plus 2% Triton X-100) and blocked in 1% FCS in PBS
(blocking buffer) for 2 h at 4 C. Serum samples were serially diluted in blocking buffer and applied to the ELISA plates in triplicate. After a 2-h incubation at room temperature with gentle
rocking, ELISA plates were washed three times with wash buffer.
TNP-bound serum antibodies were detected using 100 g/well
HRP-conjugated isotype-specific antibodies (Southern Biotechnology Associates, Inc.) diluted 1:5,000 in blocking buffer. Plates
were incubated at room temperature for 1 h with gentle rocking,
washed, and developed using ABTS (Sci-Mart) containing H2O2
as a substrate. Optical densities (OD450) were read at 405 nm (Titertek). For each isotype, a standard curve was generated based on
OD450 values using sera from a series of immunized WT mice.
Subsequently, the experimental samples were serially diluted such
that at least two values fell into the linear range of the standard
curve. Concentrations of TNP-specific antibodies are shown as
relative units compared with the standard curve determined for
each specific isotype.
Cell Culture, Transfections, and Immunoblotting. Cells were
cultured in DMEM with 10% FCS. For immunochemistry, cells
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were plated in coverslips at 5  104 cells per well in 24-well
plates. For immunoprecipitation and immunoblotting, cells
were plated on 100-mm dish at the density of 1.8  106 cells
per dish, and cells were transfected using SuperFect (QIAGEN)
according to manufacturers instructions. At 36 h after transfection, cells were washed with ice cold PBS and then lysed in cold
NP-40 lysis buffer (50 mM Tris-Cl, pH 7.6, 150 mM NaCl, 10
mM NaF, 1 mM Na3VO4, 10% glycerol, 1% NP-40, 1 mM
phenylmethylsulfonyl fluoride, 1 g/ml each of leupeptin, aprotinin, and pepstatin) for 10 min at 4 C. Plates were then scraped
and crude lysates cleared by centrifugation at 14,000 g for 10
min at 4 C. For immunoprecipitation, total lysates were incubated with 2  g of antibodies and a 50:50 slurry of protein
A–conjugated Sepharose beads (Amersham Biosciences) with rotation for 3 h at 4 C. Immunoprecipitates were washed four times
with cold NP-40 lysis buffer, resuspended in 2 SDS sample
buffer, and analyzed by Western blotting following standard
procedures. Primary antibodies were developed with HRP-conjugated secondary antibodies (Bio-Rad Laboratories, Inc.) and
visualized by chemiluminescence (Amersham Biosciences). For
analyses of tyrosine phosphorylation events, stimulated cells
were lysed in RIPA buffer (PBS, 1% NP40, 0.5% deoxycholate,
0.1% SDS, 10 mM EDTA) supplemented with a protease and
phosphatase inhibitor cocktail (Boehringer). Postnuclear lysates
were prepared, resolved by SDS-PAGE, and analyzed with antibodies to phosphotyrosine (4G10; Upstate Biotechnology). Immune complexes were detected by enhanced chemiluminescence (Amersham Biosciences).
Ca2 Fluxes. Ca2 signaling was measured by preloading purified B or T cells with either Indo-1-AM or Fluo-4-AM (Mo-

lecular Probes) at the concentration of 3–5 g/ml, 106 cells/ml at
37 C for 45 min, with occasional vortexing. In some experiments, cells were stained with anti–CD4-APC conjugates after
loading to allow “gating” on CD4 T cells during analyses. Cells
were washed, resuspended in complete media, and analyzed by
flow cytometry by running unstimulated samples for 20 s to establish the baseline, and then cells were stimulated by addition of
either anti-IgM antibodies (Jackson ImmunoResearch Laboratories) or anti-CD3 immediately followed by cross-linking with
anti–hamster antibodies (BD Biosciences) at the indicated concentrations. Ca2 fluxes were measured for 8 min followed by the
addition of ionomycin for additional 1 min at 0.5 g/ml.
Intracellular Staining for Phospho-p44/42 MAPK (pErk). To
determine Erk activation in T cells, intracellular staining was
done. Thymocyte cell suspensions were prepared directly in prewarmed (37 C) 4% paraformaldehyde (2% final) to fix cells, immediately followed by permeabilization in 100% ice cold methanol for 30 min. As a positive control, fresh cells were stimulated
with PMA (20 ng/ml) in PBS for 5 min. Cells were stained with
phospho-p44/42 MAPK (pErk) (Thr202/Tyr204, E10 clone;
Cell Signaling Technology) in the presence of Fc-block at room
temperature for 15–30 min. Anti–mouse IgG1-PE and CD4 CyC
were added to each sample and incubated at RT for 15–30 min.
Cells were analyzed by flow cytometry and gated electronically
based on expression of surface markers as indicated.
Online Supplemental Material. Fig. S1 depicts analyses of lymphocyte development in Vav2ko and Vav3ko mice. Flow cytometry analyses of thymocytes, splenocytes, LN, and BM cells from
WT mice (WT), Vav2ko (Vav2), or Vav3ko (Vav3) mice are
shown. Fig. S2 shows the strategy for generation of Vav3-defi-

Figure 1. Involvement of Vav proteins in antigen receptor signaling in T and B lymphocytes. (A) Expression of the Vav1, Vav2, and Vav3 in lymphocytes.
Cells were harvested, and equal amounts of total RNA (5 g) were analyzed by RNase protection assay with specific riboprobes as indicated. As a loading
control, the same preparations of RNAs were hybridized with antisense probe for GAPDH (bottom). This experiment was performed several times using
different sets of specific probes with similar results. (B) TCR- and BCR-induced tyrosine phosphorylation of Vav1, Vav2, and Vav3. Freshly isolated LN
T cells (top) or splenic B cells (bottom) were either left untreated ( ) or treated with stimulatory antigen receptor antibodies () for 2 h as indicated. Vav
proteins were immunoprecipitated (i.p.) from cell lysates with specific antibodies, and the level of phosphotyrosine was analyzed by immunoblotting with
antiphosphotyrosine (anti-PY) antibodies (4G10; Upstate Biotechnology). The mobilities of Vav proteins are indicated. The data are representative of
three independent experiments; the relative levels of phosphorylation of individual Vav proteins varied somewhat between experiments. (C) Jurkat T
cells were transfected with GFP-tagged full-length Vav1, Vav2, or Vav3 cDNA constructs. Cells were incubated for 16–24 h and then either left untreated or
treated with stimulatory anti-CD3 antibodies for 5 h, cytospun, and processed for immunofluorescense microscopy. Staining with rhodamine-phalloidine
(red, top) visualized accumulations of F-actin (patches) indicated by white arrows. GFP fluorescence is shown in green (middle). Two colors were
merged (bottom) to visualize staining overlap.
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Figure 2. Defective lymphocyte development in Vav-deficient mice. (A) Impaired development of Vav-deficient T cells. Single cell suspensions of
thymocytes or LN cells from WT mice, Vav1ko (Vav1), Vav1/2ko (Vav1/2), Vav1/3ko (Vav1/3), Vav2/3ko (Vav2/3), or Vav1/2/3ko (Vav1/2/3) mice
were counted and stained with fluorescent antibody conjugates and analyzed by flow cytometry as indicated. DN thymocytes were gated as live cells that
did not stain with CD4, CD8, B220,  TCR, Gr1, and Mac1, as described in Materials and Methods. Total numbers and percentages of gated lymphocyte
populations are shown for representative samples (n  5). (B) Impaired development of Vav-deficient B cells. Cell suspensions of BM or spleen samples
were prepared as above and stained and analyzed by flow cytometry as indicated. Total numbers and percentages of gated lymphocyte populations are
shown for representative samples (n  5). Data are displayed as dot plots with logarithmic scale.

cient mice. Southern blotting analyses of targeted ES cells used to
generate chimeric mice and their offspring and Western blotting
analyses of Vav3ko splenocyte lysates with Vav3-specific antibodies showing no full-length or truncated Vav3 protein present are
also shown. Fig. S3 presents analyses of humoral TD responses
in Vav3-deficient mice. Concentrations of TNP-specific IgM,
IgG1, IgG2b, and IgG3 antibodies analyzed at various time points
post-primary or secondary immunization with TNP-conjugated
keyhole hemagglutinin protein (TNP-KLH) are shown. Fig. S4
presents analyses of cytokine production by Vav-deficient T cells
showing defective IL-2 and IFN production. Figs. S1–4 are
available online at http://www.jem.org/cgi/content/full/jem.
20030874/DC1.

Results
All Three Vav Proteins Are Tyrosine Phosphorylated and Recruited by Antigen Receptors in Primary T and B Lymphocytes.
Unlike Vav1, whose expression is predominantly restricted
to hematopoietic lineage cells, Vav2 and Vav3 are expressed more broadly (16, 17). To examine their expression
1599
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in lymphocyte subsets, we used an RNase protection assay
and found that Vav1, Vav2, and Vav3 were all expressed in
immature and mature populations of T and B cells (Fig.
1 A; unpublished data). Although tyrosine phosphorylation
of Vav1 in response to antigen receptor stimulation in lymphocytes is well documented (19, 20), less is known about
phosphorylation of Vav2 or Vav3 in T and B lymphocytes
(21, 22, 35, 36). To this end, we stimulated freshly isolated
LN T cells or splenic B cells with either anti-CD3 or with
anti-IgM antibodies, respectively, and found that all three
Vav proteins were inducibly tyrosine phosphorylated (Fig.
1 B). Moreover, since Vav1 is implicated in actin cytoskeleton changes that accompany formation of the immunological synapse (23, 24, 37), we examined the localization
of all three Vav proteins fused to a GFP tag in anti-CD3–
stimulated Jurkat T cells (Fig. 1 C). We found that upon
treatment with anti-CD3 antibodies, each one of the Vav
fusion proteins colocalized with antigen receptor formed
caps and F-actin patches (Fig. 1 C). Together, these results
indicate that all three Vav family proteins become tyrosine

Downloaded from jem.rupress.org on September 13, 2011

The Journal of Experimental Medicine

Published November 17, 2003

phosphorylated and colocalize with actin at the TCR caps
in lymphocytes.
Mice with Combined Vav Deficiencies Reveal a Major Compensatory Role for Vav3 in T Cell Development. Previous
studies of Vav1ko mice demonstrated partial defects in T
cell development and activation (27–30); however, Vav1ko
T cells still retained substantial developmental and functional capability. To determine if this was due to the expression of Vav2 in these cells, we examined mice lacking
both Vav1 and Vav2 (Vav1/2ko). As expected based on
previous studies (27–30, 33, 34), Vav1ko mice showed diminished numbers of thymocytes and peripheral T cells
(approximately two- to threefold; Fig. 2 A), whereas
Vav2 ko mice had normal T cell development (Fig.
S1 A, available at http://www.jem.org/cgi/content/full/
jem.20030874/DC1). Vav1/2ko mice had populations of
CD4 8 (DN), CD48 (double positive [DP]), and
CD48 or CD4 8 (single positive [SP]) thymocytes and

peripheral T cells comparable to those in Vav1ko mice (Fig.
2 A). Moreover, subsets of DN thymocytes distinguished
based upon expression of CD44 and CD25 (DN1,
CD4425 ; DN2, CD4425; DN3, CD44 25; and
DN4, CD44 25 ) were similar in Vav1ko and Vav1/2ko
mice (Fig. 2 A). These experiments suggest that Vav2 has
no major function in the development of T lymphocytes in
the absence of Vav1.
To determine if Vav3 compensates for the loss of Vav1
in Vav1ko T cells, we generated Vav3-deficient (Vav3ko)
mice using standard gene targeting approaches (Fig. S2,
available at http://www.jem.org/cgi/content/full/jem.
20030874/DC1). Although Vav3ko mice showed normal
T cell development (Fig. S1 A), the lack of Vav3 significantly exacerbated the T cell phenotype of Vav1ko mice
(Fig. 2 A). Thus, populations of DN4, DP and SP thymocytes, and peripheral T cells were all significantly reduced in Vav1/3ko mice compared with Vav1ko mice (Fig.

Figure 3. Late developmental block in
Vav-null B cells. (A) Late developmental
block at the T1/T2 stage and accumulation
of NF cells in Vav-null mice. Splenocyte
suspensions from WT mice or Vav1/2/3ko
(Vav1/2/3) were stained and analyzed by
flow cytometry as indicated. Percentages of
gated lymphocyte populations are shown
for representative samples (n  3). Total
numbers of corresponding populations are
shown in Table I. Data are displayed as dot
plots with logarithmic scale. (B) Differential
requirement for Vav family proteins in T
and B lymphocyte development and MAP
kinase activation. Schematic representation
of developmental defects of lymphoid cells
observed in Vav1/2/3ko (Vav1/2/3) mice.
See Results and Discussion for details.

1600

Lymphocyte Defects in Mice Lacking All Vav Proteins

Downloaded from jem.rupress.org on September 13, 2011

The Journal of Experimental Medicine

Published November 17, 2003

Published November 17, 2003

Table I. B Lymphocyte Populations in Vav-null Mice

Wild type
Vav null

Total

Newly formed

T1

T2

Follicular

MZ

94.5  38.3
88.7  7.6

4.5  1.4
20.6  3.9

5.3  2.9
15.6  3.5

6.3  2.0
2.5  1.1

12.9  8.6
0.7  0.3

1.9  1.3
0.5  0.1

2 A), indicating that Vav3 is critical for development of T
cells lacking Vav1.
Vav-null T Cells Are Developmentally Blocked at the DN
Stage. To establish the role of the entire family of Vav
proteins in lymphocytes, we generated mice lacking Vav1,
Vav2, and Vav3 (Vav1/2/3ko). These mice were viable and
showed no gross abnormalities of internal organs upon histological examination at 4–6 wk of age (unpublished data).
Vav1/2/3ko mice had drastically reduced thymocyte numbers (50- to 100-fold compared with WT) with few DP
and SP cells or peripheral T cells (which were reduced by
100-fold compared with WT) (Fig. 2 A). The block in
thymocyte development occurred at the DN3 to DN4 tran-

sition, since Vav1/2/3ko mice showed predominantly DN3
cells and only few DN4 cells (Fig. 2 A). In addition, large
DN4 cells were essentially absent in Vav1/2/3ko mice (2%
compared with 15–20% in WT; unpublished data). These
results clearly demonstrate that Vav proteins are indispensable in T cell development, although we could still detect
few DP cells in the thymus and few T cells in the peripheral
lymphoid organs of Vav-null mice suggesting some “leakiness” of the developmental block (Fig. 2 A and Fig. 3 B).
Notably, mice lacking Vav2 and Vav3 (Vav2/3ko)
showed no obvious T cell abnormalities (Fig. 2 A), indicating that expression of Vav1 alone is sufficient to support T
cell development. Thus, these results suggest a hierarchy of

Figure 4. Failure to mount antigen-specific humoral responses in Vav-null mice. (A) TD responses. WT or Vav1/2/3ko mice were immunized with
trinitrophenyl (TNP)-conjugated keyhole haemaglutinin protein (TNP-KLH), and the concentrations of TNP-specific IgM, IgG1, IgG2b, and IgG3
antibodies were analyzed at various time points post-primary or secondary immunization by antigen-specific ELISA as described in Materials and Methods.
Each symbol represents an individual mouse, and mean values are indicated by horizontal bars. WT mice () and Vav1/2/3ko mice (). (B) T-independent
type 2 (TI-2) responses. WT or Vav1/2/3ko mice were immunized with a TI-2 antigen, TNP-Ficoll, and the concentrations of TNP-specific IgM and
IgG3 antibodies were analyzed as in A. Each symbol represents an individual mouse and mean values are indicated by horizontal bars. WT mice () and
Vav1/2/3ko mice ().
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Cells from spleens of WT and Vav1/2/3 ko (Vav-null) mice were counted and stained for cell surface expression of B220, IgM, IgD, CD23, and CD21/
35, as shown in Fig. 3 A, and analyzed by flow cytometry. Numbers of indicated populations are shown for newly formed (NF or
B220+CD21 CD23 ), transitional 1 (T1 or B220+CD21 loIgMhiIgDlo), transitional 2 (T2 or B220+CD21 hiIgMhiIgDhi), follicular (FO or
B220+CD21intCD23hiIgMloIgDhi), and marginal zone (MZ or B220+CD21 hiCD23lo) cells. Data are presented as means  SDs and represent
multiples of 106 cells (n = 3). Total cells were counted by gating live lymphoid cells.

Vav proteins in T cell development with Vav1 playing a
major role that can be compensated for, at least in part, by
Vav3. On the other hand, a compensatory function of
Vav2 is only apparent in developing T cells lacking both
Vav1 and Vav3.
Vav-null B Cells Show a “Leaky” Developmental Block at
the T1/T2 Stage. In contrast to T cells, immature populations of B cells in BM including progenitors (B220low
CD43hiIgM ), precursors (B220CD43lowIgM /low), and
immature (B220CD43lowIgM) B cells appeared to develop normally in mice with single or combined Vav deficiencies (Fig. 2 B; Fig. S1 B; unpublished data). Notably,
Vav1/2ko, Vav1/3ko, and Vav1/2/3ko mice showed reduced
populations of “recirculating” BM B220hiIgMlo B cells (Fig.
2 B). Mature IgMloIgDhi B cells appeared normal in Vav2ko,
Vav3ko, and Vav2/3ko mice and marginally decreased in
Vav1ko and Vav1/3ko mice (Fig. 2 B and Fig. S1 B) but were
more significantly decreased in Vav1/2ko and Vav1/2/3ko
mice (approximate two- to threefold reduction compared
with WT; Fig. 2 B). To more precisely determine the developmental defect in B cells lacking all Vav proteins, we used
anti-CD21/35 and anti-CD23 antibodies to subdivide B
cells into populations of newly formed (NF or B220
CD21 CD23 ), transitional 1 (T1 or CD21loIgMhiIgDlo),
transitional 2 (T2 or CD21hiIgMhiIgDhi), follicular (FO or
CD21intCD23hiIgMloIgDhi), and marginal zone (MZ or
CD21hiCD23lo) cells. Strikingly, these analyses revealed

drastically reduced subsets of FO and MZ B cells in
Vav1/2/3ko mice compared with WT (Fig. 3 A and Table
I). Moreover, T2 cells appeared slightly reduced (approximately twofold) in Vav1/2/3ko mice, whereas the numbers of T1 and NF cells were increased, indicating a
“leaky” developmental block at T1/T2 stage (Fig. 3, A
and B; Table I).
Vav-null Mice Fail To Mount Humoral Responses to TD and
TI Antigens. To determine if lymphocytes generated in
Vav-null mice are functional in vivo, we immunized
Vav1/2/3ko or WT mice with the TD antigen, trinitrophenyl (TNP)-conjugated keyhole hemagglutinin (TNPKLH), and measured the concentrations of TNP-specific
IgM, IgG1, IgG2b, and IgG3 antibodies at various time
points post-primary and secondary immunization (Fig. 4 A).
In this regard, although Vav1ko and Vav2ko mice were
shown previously to have impaired production of switched
antibodies against TD antigens, their IgM responses were
completely normal (33, 38). In contrast, Vav3ko mice
showed robust humoral responses and the ability to isotype
switch (Fig. S3, available at http://www.jem.org/cgi/
content/full/jem.20030874/DC1). Strikingly, Vav1/2/3ko
mice completely failed to produce any detectable antiTNP–specific IgM antibodies at any time point after
immunization (Fig. 4 A). Moreover, Vav1/2/3ko mice
generated no detectable IgG1, IgG2b, or IgG3 anti-TNP
antibodies (Fig. 4 A). These data demonstrate that the en-

Figure 5. Defective proliferative responses and blast formation by Vav-deficient T cells. (A) Impaired proliferation of antigen receptor–stimulated T
cells lacking Vav proteins. Purified LN T cells from WT (black bars), Vav1ko (Vav1, white dotted bars), Vav1/2ko (Vav1/2, black dotted bars), Vav1/3ko
(Vav1/3, white bars), Vav2/3ko (Vav2/3, horizontal striped bars), or Vav1/2/3ko (Vav1/2/3, gray bars) mice were cultured in either media alone or in
the presence of stimulatory anti-CD3 and/or anti-CD28 antibodies as indicated. Proliferation was determined at 48 h by 3H-thymidine incorporation
and scintillation counting. The data are displayed as raw cpm values. The results are representative of three independent experiments. All assays were
conducted in triplicates, and SDs are shown as vertical lines. (B) Defective blast formation of antigen receptor–stimulated Vav-deficient T cells. LN T
cells from indicated mice were cultured in either media alone or in the presence of stimulatory anti-CD3 and anti-CD28 antibodies, or with phorbol
myristyl acetate (PMA) and ionomycin (I) for 36 h as described in Materials and Methods. Cells were then harvested and analyzed by flow cytometry.
Forward scatter dot blots of CD4 gated cells in representative samples are shown (n  5) and numbers represent percentages of blasting cells.
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tire Vav family is absolutely required for generation of antigen-specific TD humoral responses.
To determine if Vav-null mice could mount TI-2 responses, we immunized WT or Vav1/2/3ko mice with
TNP-conjugated Ficoll (TNP-Ficoll) and determined concentrations of TNP-specific IgM and IgG3 antibodies after
primary or secondary immunization. In this regard, Vav1ko
mice were shown previously to generate normal responses
to TI-2 antigens (38), although Vav2ko and Vav1/2ko mice
had defective TI-2 responses (33, 34). Strikingly, Vav1/2/
3ko mice completely failed to produce any detectable antiTNP antibodies in response to TI-2 antigen at any time
point after immunizations (Fig. 4 B). Together, these data
show a strict requirement for Vav proteins in mounting
both TD and TI humoral responses.
Vav3 Functionally Compensates for the Loss of Vav1 in
T Cell Proliferative Responses. Next, we examined in vitro
proliferative responses of T cells lacking Vav proteins.
Consistent with previous reports (27–30), Vav1ko T cells
showed a partial defect in proliferative responses to stimulation with anti-CD3 with or without anti-CD28 antibodies as measured by 3H-thymidine incorporation (Fig.
5 A). Notably, Vav1/2ko T cells proliferated equally to
Vav1ko T cells, indicating that Vav2 does not substantially
compensate for the loss of Vav1 (Fig. 5 A). Strikingly,
however, T cells from Vav1/3ko or Vav1/2/3ko mice vir-

tually failed to incorporate 3H-thymidine in response to
stimulation with anti-CD3 and anti-CD28 antibodies
compared with WT (Fig. 5 A). These data demonstrate
that, unlike Vav2, Vav3 appears critical for function of T
cells that do not express Vav1. T cells from Vav2ko or
Vav3ko mice showed normal proliferative responses, indicating that neither of these proteins is essential in T cells
expressing Vav1 (unpublished data).
As an alternative measure of T cell proliferation, we also
assayed for the production of large (blasting) cells. In this
assay, nonstimulated fresh LN T cells remained small at
various time points in culture (indicated by their low forward and side scatter; Fig. 5 B, left). On the other hand,
cultures of WT T cells stimulated with anti-CD3 and antiCD28 antibodies contained predominantly blasting cells
(Fig. 5 B, middle). In contrast, the ability of Vav1ko or
Vav1/2ko T cells to generate blasts was reduced by approximately three- to fourfold (Fig. 5 B), whereas T cells from
Vav1/3ko or Vav1/2/3ko mice virtually failed to produce
blasts in response to anti-CD3 and anti-CD28 antibody
stimulation. Thus, unlike Vav1ko T cells, which retain a
significant proliferative capacity, T cells lacking both Vav1
and Vav3 have severely disrupted proliferative responses.
All T cells responded normally to PMA and ionomycin
(Fig. 5 B; unpublished data), indicating no intrinsic cell cycle defects in Vav-deficient T cells.

Figure 6. Defective proliferative responses and blast formation by Vav-deficient B cells. (A)
Impaired proliferation of antigen
receptor–stimulated B cells lacking
Vav proteins. Purified spleen B
cells from WT (black bars),
Vav1ko (Vav1, white dotted
bars), Vav1/2ko (Vav1/2, black
dotted bars), Vav1/3ko (Vav1/3,
diagonal striped bars), or Vav1/
2/3ko (Vav1/2/3, white bars)
mice were cultured in either
media alone or in the presence of stimulatory anti-Ig antibodies as indicated (and as described
in Materials and Methods). Proliferation was determined at 48 h by 3H-thymidine incorporation
and scintillation counting. The data are displayed as raw cpm values. The results are representative
of three independent experiments. All assays were conducted in triplicates, and SDs are shown
as vertical lines. (B) Defective blast formation of antigen receptor–stimulated Vav-deficient B
cells. B cells from indicated mice were cultured in either media alone, or in the presence of
stimulatory anti-Ig antibodies, or with phorbol myristyl acetate (PMA) and ionomycin (I) for
36 h as described in Materials and Methods. Cells were then harvested and analyzed by flow
cytometry. Forward scatter dot blots of B220-gated cells in representative samples are shown
(n  5), and numbers represent percentages of blasting cells. (C) Defective proliferation of
Vav-null FO B cells. B cells from indicated mice were cultured in either media alone or in the
presence of stimulatory anti-Ig antibodies and analyzed as in B. Forward scatter blots of gated
FO cells are shown with percentages of blasting cells. The results are representative of three
independent experiments.
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Figure 7. Disruption of Ca2
signaling in Vav-null lymphocytes. (A) LN T cell and spleen B
cells (B) were loaded with Fluo4AM as described in Materials and
Methods. T cell suspensions
were also surface stained with
anti-CD4 antibodies conjugated
to APC. Cell suspensions were
analyzed by flow cytometry.
Samples were run at 103 cells/s
for 15 s to determine background, and then for an additional 7 min after stimulation. T
cells were stimulated by the addition of anti-CD3 antibodies
(2C11) immediately followed by
anti–hamster antibodies; B cells
were stimulated by the addition
of anti-IgM antibodies at indicated
concentrations. Data was analyzed
using FlowJo software and displayed as histograms of relative
fluorescence intensity over time
(in seconds). Representative
analyses are shown (n  3).

In addition, we examined cytokine production by T
cells in response to TCR stimulation and found that the
production of IL-2 and IFN appeared equally diminished
in Vav1ko and Vav1/2ko T cells compared with WT but
was virtually undetectable in Vav1/3ko and Vav1/2/3ko T
cells (Fig. S4, available at http://www.jem.org/cgi/
content/full/jem.20030874/DC1). Together, these results
demonstrate that in contrast to mice lacking individual Vav
1604

proteins no functional T cells can be generated in mice
lacking all Vav family members. Moreover, individual Vav
proteins contribute unevenly in this lineage, since Vav3 but
not Vav2 has a major compensatory function.
Vav-null B Cells Fail To Proliferate in Response to Ig Receptor Stimulation. To determine if B cells developing in
Vav-deficient mice still retain their ability to proliferate in
vitro in response to stimulation with anti-Ig antibodies, we
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used 3H-thymidine incorporation assay. Although responses of Vav1ko B cells to Ig cross-linking were comparable to WT, proliferation of Vav1/2ko B cells was severely
reduced (Fig. 6 A). Thus, consistent with previous reports
(33, 34), Vav1 and Vav2 appear to overlap functionally in
B cells. Vav1/3ko B cells also showed diminished proliferation, whereas Vav1/2/3ko B cells neither incorporated 3Hthymidine nor produced blasting cells in response to anti-Ig
stimulation (Fig. 6, A and B). Notably, all B cells proliferated vigorously to stimulation with PMA and ionomycin
(Fig. 6 B).
In normal mice, only mature B cells respond to Ig receptor cross-linking with proliferation, whereas the majority of
immature cells undergo cell death. Because Vav1/2/3ko B
cells show a reduction of mature (FO) B cells and a relative
increase in the proportion of immature (NF) cells, it is possible that the failure of such cells to proliferate and to incorporate 3H-thymidine is a reflection of these developmental
abnormalities. To directly test the ability of mature (FO)
Vav1/2/3ko B cells to proliferate, we used flow cytometry
and showed that the residual FO B cells present in Vav1/2/
3ko mice failed to respond to stimulation with anti-Ig antibodies (Fig. 6 C), demonstrating that the Vav family proteins are essential for in vitro B cell proliferative responses
to anti-Ig stimulation.
The Vav Family Proteins Are Indispensable for Ca2 Signaling in Both T Cells and B Cells. To determine if intracellular signaling was impaired by the loss of Vav function, we
examined the ability of Vav-deficient T and B cells to mobilize Ca2 ions. Ca2 fluxes induced by anti-CD3 antibody cross-linking were diminished in Vav1ko T cells (Fig.

7 A), consistent with previously published data (23, 24, 29).
However, Ca2 fluxes were totally disrupted in Vav1/2/3ko
T cells even under maximal stimulation conditions (Fig.
7 A). In contrast, Vav1ko, Vav1/2ko, Vav1/3ko, Vav2ko,
Vav3ko, and Vav2/3ko B cells had Ca2 fluxes comparable
to WT when stimulated with maximal doses of anti-Ig antibodies (Fig. 7 B; unpublished data), whereas Vav1ko,
Vav1/2ko, and Vav1/3ko B cell Ca2 fluxes were only minimally reduced at lower doses of stimulatory antibodies
(Fig. 7 B; unpublished data). Notably, anti-Ig induced
Ca2 responses were severely disrupted in Vav1/2/3ko B
cells even under maximal stimulation conditions (Fig. 7 B).
Together, these data indicate that the Vav family is indispensable for Ca2 signaling downstream of both the TCR
and BCR.
Vav-null Mice Reveal a Differential Requirement for Vav Proteins in Erk Activation in T Cells and B Cells. Activation of
Ras and MAP kinases is crucial for the induction of lymphocyte proliferation and cytokine production. To examine if the loss of Vav perturbed the ability of T cells to activate the Ras/MAPK pathway, we probed immunoblots
with phospho-specific antibodies that recognize active
forms of the p44 and p42 MAP kinases (Erk-1 and Erk-2).
In this regard, Vav1ko T cells showed attenuated Erk-1/2
activation in response to anti-CD3 antibodies (39 and unpublished data), whereas Vav1/2/3ko T cells virtually failed
to activate Erk-1/2 in response to this treatment (Fig. 8 A).
Importantly, Erk-1/2 could still be induced in Vav1/2/3ko
T cells by PMA treatment, indicating a defect upstream of
DAG production (Fig. 8 A). Surprisingly, anti-Ig crosslinking resulted in normal Erk-1/2 activation in Vav1/2/

Figure 8. Disruption of Erk1/2 activation in Vav1/2/3ko T
cells but not B cells. (A) Impaired
TCR induced Erk-1/2 phosphorylation in WT and Vav1/2/
3ko T cells. Freshly isolated LN T
cells were either left untreated
(0 ) or treated with anti-CD3
antibodies immediately followed
by anti–hamster antibodies for
the indicated period of time.
PMA was used as a positive
control at 100 ng/ml for 5 min.
Cell lysates were prepared by
direct lysis with SDS buffer followed by boiling and sonication
and then analyzed by immunoblotting with anti–phosphop42/p44 Erk-1/2 antibodies (as
described in Materials and
Methods). Protein loading was verified by stripping and reprobing blots with anti–Erk-2 antibodies. The data are representative of three independent
experiments. (B) Disruption of Erk-1/2 activation in thymocytes undergoing “ selection.” Thymocytes from WT or Vav1/2/3ko mice were surface
stained with CyC-labeled anti-CD4 and anti-CD8 and FITC-labeled anti-CD25 antibodies, and were permeabilized and stained with PE-labeled anti–
phospho-p42/p44 Erk-1/2 antibodies as described in Materials and Methods. Histograms representing phospho–Erk-1/2 staining intensity are shown for
gated populations of CD4 CD8 CD25 “large” cells from WT or Vav1/2/3ko mice as indicated. (C) Normal BCR induced Erk-1/2 activation in
Vav1/2/3ko B cells. Freshly isolated spleen B cells were either left untreated (0 ) or treated with anti-Ig antibodies or PMA and analyzed as in A. (D)
Normal Erk-1/2 activation in large pro–B cells. BM cells from WT or Vav1/2/3ko mice were surface stained with CyC-labeled anti-B220 and
FITC-labeled anti-CD43 antibodies and then were permeabilized and stained with PE-labeled anti–phospho-p42/p44 Erk-1/2 antibodies as described
in Materials and Methods. Histograms representing phospho–Erk-1/2 staining intensity are shown for gated populations of B220loCD43 large cells
from WT or Vav1/2/3ko mice as indicated.
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3ko B cells and in B cells lacking any other combination of
Vav proteins (Fig. 8 C; unpublished data). Thus, it appears
that in contrast to T cells, Vav proteins are not required for
Erk-1/2 activation in B cells, indicating a fundamentally
distinct mechanism of antigen-receptor signal transduction
in cells of the T and B lineages.
Since Ras/MAPK signaling is implicated in the DN to
DP transition in the thymus and pre–B cell differentiation
and BM egress (2–9), we investigated if Erk-1/2 activity
could be detected in large DN3 cells and in large pro–B
cells in WT and Vav1/2/3ko mice. In this regard, intracytoplasmic staining of ex vivo BM cells revealed increased levels of activated Erk-1/2 in large pro–B cells in both WT
and Vav1/2/3ko mice, whereas large DN3 cells in Vav1/2/
3ko mice had significantly reduced levels of activated Erk1/2 compared with WT (Fig. 8 B). Phospho–Erk-1/2
staining was equivalent in all cells treated with PMA (unpublished data). Collectively, these data indicate that the
loss of Vav proteins leads to a disruption of Ras/MAP kinase signaling in both immature and mature T cells but not
in developing or mature B cells.

Discussion
In this report, we examined the roles of Vav Rho–guanine nucleotide exchange factors in lymphocytes. We describe the generation and analyses of mice in which all
known members of the Vav family, Vav1, Vav2, and Vav3,
have been inactivated via gene targeting. We show that in
the lymphoid system this combined Vav deficiency prevents the development of functionally mature T or B cells
and disrupts signaling downstream of both T and B cell antigen receptors.
In primary lymphocytes, all three Vav proteins are functionally coupled to signaling events downstream of the
TCR and the BCR as indicated by their inducible tyrosine
phosphorylation and recruitment to structures associated
with the immunological synapse. Despite their common
ancestry, conserved structural features, and the ability of
each Vav protein to couple with lymphocyte antigen receptors, individual Vav proteins have both common and
specialized functions in lymphocytes in vivo. For example,
our analyses of Vav1/2ko mice indicate that Vav2 does not
functionally compensate for Vav1 in T cells as it does in
B cells (33, 34). Thus, Vav2 may be specifically involved in
signaling downstream of the BCR but not the TCR. Nevertheless, Vav2 is able to substitute for some functions of
Vav3, since there is a more severe developmental block of
Vav1/2/3ko thymocytes compared with Vav1/3ko. On the
other hand, analyses of lymphocytes in Vav2/3ko mice indicate that Vav1 itself is sufficient to support apparently normal development and function of T and B cells, suggesting
mainly auxiliary role(s) for Vav2 and Vav3. Thus, although
we have not yet identified any strictly nonredundant functions for any of the individual Vav proteins, genetic evidence presented in this report clearly demonstrates that of
the 50 Rho-GEFs that exist in mammalian cells (18) the
1606

Vav family Rho-GEFs play a role that is both specialized
and nonredundant in T and B lymphocytes (Fig. 3 B).
Developing T and B cells receive differentiation and expansion signals from distinct classes of surface receptors,
such as cytokine receptors and the pre-TCR or pre-BCR,
all of which could conceivably involve Vav proteins. For
example, Vav has been implicated in signaling by receptors
sharing the common -chain, which have crucial functions
in lymphocyte ontogeny (1). In this regard, normal development of DN1, DN2, and DN3 thymocytes as well as
pro–B and pre–B cells in Vav1/2/3ko mice indicates that
Vav proteins are not required in signaling by receptors such
as the IL-7R. In fact, both WT and Vav1/2/3ko BM cells
proliferate in response to IL-7 treatment in vitro (unpublished data). Moreover, the accumulation of immature
populations of B cells, including NF and T1 (Table I), in
Vav1/2/3ko mice indicates that Vav proteins are not required for signaling downstream of the pre-BCR, yet they
appear essential for the transition to more mature developmental stages that may require stronger antigen receptor
signals. Clearly, our data indicate that in B lineage cells Vav
proteins are superfluous in Ras/MAPK activation through
the BCR (Fig. 8, C and D) and thus may allow for development of all immature populations of B cells in Vav1/2/
3ko mice despite the uncoupling of BCR signaling from
Ca2 fluxes. In this regard, our data are consistent with previously published reports by us and other groups that the
activation of Ras/MAPK pathway alone is sufficient to
promote development of B lineage cells beyond the pre–B
cell stage (7–9).
On the other hand, our observations indicate a critical
role for Vav in signaling by the pre-TCR (Fig. 8 B). Specifically, we show that Vav deficiency results in developmental arrest at the DN3 to DN4 transition. This block is
not due to defects in assembly and/or expression of TCR
chain genes, since a significant fraction of Vav1/2/3ko DN3
cells expressed cytoplasmic TCR chains (unpublished
data). Rather, drastically reduced numbers of DP thymocytes and large (blasting) DN3/DN4 thymocytes in
Vav1/2/3ko mice compared with WT suggest a pivotal role
for Vav proteins in pre-TCR signaling.
Several studies have implicated the activation of the Ras/
MAPK pathway as a crucial event in the induction of differentiation and expansion of both T and B cell precursors
(2–9). Given the crucial role for Ras/MAPK signaling in
the development of both T and B lineage cells (2–5, 7–9)
and the strikingly different requirement for Vav in these
cells, it is possible that Vav may not be required for regulation of MAPK, or alternatively, T and B cells may utilize
diverse mechanisms of MAPK activation. Indeed, two lines
of experimental evidence presented in this report support
the latter possibility. First, analyses of MAP kinase (Erk-1/2)
activity in antigen receptor–stimulated T cells and B cells
indicated a complete disruption of Erk-1/2 signaling in
Vav1/2/3ko T cells, which is in contrast to normal activation of Erk-1/2 in Vav1/2/3ko B cells. Second, whereas
WT “large” DN3 thymocytes showed significantly in-

Lymphocyte Defects in Mice Lacking All Vav Proteins

Downloaded from jem.rupress.org on September 13, 2011

The Journal of Experimental Medicine

Published November 17, 2003

creased Erk-1/2 activity (presumably resulting from preTCR signaling), Erk-1/2 activity was drastically reduced in
the equivalent population of Vav1/2/3ko pro–B cells. Yet,
both WT and Vav1/2/3ko “large” pro–B cells showed similarly increased Erk-1/2 activity. Together, these results
support a view in which the regulation of Ras/MAPK signaling in T and B lineage cells is fundamentally different. In
this context, recent evidence suggests that DAG-dependent
Ras guanine nucleotide release protein (Ras-GRP1) may
be specifically required in the activation of Erk-1/2 in T
cells, but not in B cells (40). In fact, the defects in Erk-1/2
activation in Vav1/2/3ko T cells resemble those observed in
RasGRP1ko T cells (Fig. 8) (40), suggesting that TCR induction of Erk-1/2 maybe regulated by Vav via PLC1
and RasGRP1. Thus, it is plausible that the TCR complex
may require DAG-dependent pathway for Erk-1/2 activation, whereas the BCR could, conceivably, use a DAGindependent mechanism, such as the one involving Grb2/
SOS. Indeed, Grb2 haplo-insufficiency in T cells resulted
in decreased activity of JNK and p38 but not Erk-1/2 (41),
consistent with such a view. Our data also indicate that the
induction of Ras/MAPK in B cells does not depend on
Ca2 signaling and, presumably, PLC activity.
In this paper, we also extended our previous studies of
Vav function in Ca2 signaling (23). We found that unlike
Vav1ko lymphocytes, which show only partial Ca2 defects,
Vav1/2/3ko T and B cells have disrupted Ca2 signaling
downstream of their antigen receptors. These data are consistent with observations that Vav may be involved in the
activation of PLC1 (42), although the exact mechanism is
still unknown. Nevertheless, our observations establish that
Vav family proteins are essential to determine the signaling
output of antigen receptors in both T cells and B cells, although they appear to differentially link the TCR and
BCR with Ras/MAPK induction.
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